Evidence map›Paper›PMID 32578741›Full record

ArticleSao Paulo medical journal = Revista paulista de medicina2020

Risk factors associated with drug therapy among elderly people with Alzheimer's disease: a cross-sectional study.

Marcela Forgerini, Maria Teresa Herdeiro, José Carlos Fernandes Galduróz, Patrícia de Carvalho Mastroianni

Abstract read
In one paragraph

Article in Sao Paulo medical journal = Revista paulista de medicina, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marcela ForgeriniDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Universidade Estadual Paulista, Araraquara, SP, Brazil.
Maria Teresa HerdeiroDepartment of Medical Sciences, Institute of Biomedicine, Universidade de Aveiro, Aveiro, Portugal.
José Carlos Fernandes GaldurózDepartment of Psychobiology, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Patrícia de Carvalho MastroianniDepartment of Drugs and Medicines, Universidade Estadual Paulista, Araraquara, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImproving knowledge and establishing strategies and policies for better patient safety are worldwide priorities.

objectiveTo evaluate drug safety among elderly people with Alzheimer's disease (AD). DESIGN AND

settingCross-sectional study among elderly people within the National AD Assistance Protocol (PCDTDA/MS) who were living in the municipality of Araraquara, Brazil, in 2017.

methodsThrough interviews conducted with relatives/caregivers of elderly people with diagnoses of AD, the following variables were evaluated: comorbidities, drug therapy used, use of potentially inappropriate medications for the elderly (PIMs), presence of potentially inappropriate interactions (PIIs) and medication regimen complexity index. Factors associated with AD severity were also evaluated. Multivariate and simple logistic regressions were applied.

results143 elderly people enrolled in PCDTDA/MS were analyzed. The majority were women (67.1%); assisted only through the public healthcare system (75.5%); polymedicated (57.4%); using at least one PIM (63.6%); presenting at least one PII (63.6%); and under drug therapy of low to medium complexity (92.2%). No semi-annual monitoring of the effectiveness of PCDTDA/MS drugs was identified. The proportion using AD drug therapy at daily doses differing from those recommended by the World Health Organization was 75.6%. However, these doses were not associated with drug risk.

conclusionThe data from this study raise the hypothesis that use of polypharmacy might show a correlation with severity of AD. The drug safety risk may be associated with comorbidities of the metabolic syndrome, anxiety and off-label use of PIMs, such as risperidone and quetiapine, and benzodiazepines (i.e. clonazepam and flunitrazepam).

Indexed as

Alzheimer DiseaseAgedBrazilCross-Sectional StudiesFemaleHumansInappropriate PrescribingMalePolypharmacyRisk Factors

Identifiers

PMID32578741
PMCPMC9671228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.